Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

Jun 24, 2026 | Press Releases

Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substanceNewly manufactured supply will support upcoming clinical trial in next development phaseKing of Prussia, Pennsylvania–(Newsfile Corp. – June 24, 2026) – Phio...

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

Jun 18, 2026 | Press Releases

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in Phio Pharmaceuticals, to attend the live, interactive presentation and one-on-one meetingsKing of Prussia, Pennsylvania–(Newsfile Corp. – June...

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

May 26, 2026 | Press Releases

Live Presentation and Q&A: Thursday, May 28, 2026 12 PM EDTKing of Prussia, Pennsylvania–(Newsfile Corp. – May 26, 2026) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using...

Phio Pharmaceuticals Announces “Innovations in Skin Cancer Treatment and Prevention” in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026

May 12, 2026 | Press Releases

Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio CEO Robert Bitterman and Force Family Office CEO Steven SaltzsteinKing of Prussia, Pennsylvania–(Newsfile...

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 7, 2026 | Press Releases

Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology DataKey Development Agreements Secured for Nonclinical Toxicology and U.S. cGMP Clinical Supply ManufacturingKing of Prussia,...